Stockscreener 앱 받기
35.25
0.14%
0.05
시간 외 거래:
35.25
전일 마감가:
$35.20
열려 있는:
$35.51
하루 거래량:
611.93K
Relative Volume:
0.94
시가총액:
$2.02B
수익:
$681.88M
순이익/손실:
$122.63M
주가수익비율:
16.71
EPS:
2.11
순현금흐름:
$220.18M
1주 성능:
+1.56%
1개월 성능:
+10.54%
6개월 성능:
-12.88%
1년 성능:
+10.02%
1일 변동 폭
$35.04
$36.05
1주일 범위
$34.13
$37.21
52주 변동 폭
$26.47
$41.61
하모니 바이오 Stock (HRMY) Company Profile
명칭
Harmony Biosciences Holdings Inc
전화
(484) 539-9800
주소
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
HRMY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
35.25 | 1.99B | 681.88M | 122.63M | 220.18M | 2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
하모니 바이오 Stock (HRMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-17 | 개시 | H.C. Wainwright | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-09-10 | 개시 | UBS | Buy |
| 2024-06-21 | 개시 | Citigroup | Buy |
| 2024-01-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-09-25 | 다운그레이드 | Goldman | Neutral → Sell |
| 2023-09-07 | 개시 | Berenberg | Buy |
| 2023-04-20 | 개시 | BofA Securities | Neutral |
| 2022-10-14 | 업그레이드 | Janney | Neutral → Buy |
| 2022-10-14 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-04 | 개시 | Raymond James | Outperform |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-03-29 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-14 | 개시 | Goldman | Neutral |
| 2020-09-14 | 개시 | Jefferies | Buy |
| 2020-09-14 | 개시 | Piper Sandler | Overweight |
모두보기
하모니 바이오 주식(HRMY)의 최신 뉴스
Is Harmony Biosciences Holdings Inc. a good long term investmentTremendous wealth creation - Autocar Professional
What drives Harmony Biosciences Holdings Inc. stock priceExceptional profit velocity - Autocar Professional
Truist Securities initiates Harmony Biosciences stock with Buy rating - Investing.com Australia
Truist Securities initiates Harmony Biosciences stock with Buy rating By Investing.com - Investing.com UK
Truist Securities Initiates Coverage on Harmony Biosciences (HRM - GuruFocus
H.C. Wainwright reiterates Buy rating on Harmony Biosciences stock - Investing.com
Truist Securities Starts Harmony Biosciences Holdings Inc. (HRMY) at Buy - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
What analysts say about Harmony Biosciences Holdings Inc. stockExplosive returns - Autocar Professional
Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again - MSN
Harmony Biosciences Holdings Inc. Stock Analysis and ForecastBreakout portfolio performance - jammulinksnews.com
Transcript : Harmony Biosciences Holdings, Inc. Presents at H.C. Wainwright "HCW@Home" Series, Jul-17-2025 10 - MarketScreener España
Harmony Biosciences Balances Growth Potential With Clinical Milestones - Finimize
Harmony Biosciences to Participate in H.C. Wainwright HCW@Home Series - MarketScreener
When (HRMY) Moves Investors should Listen - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS) and Harmony Biosciences Holdings (HRMY) - The Globe and Mail
Mizuho Reaffirms “Outperform” on Harmony Biosciences (HRMY) for BP1.15205 Data - MSN
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series - BioSpace
3 Reasons Growth Investors Will Love Harmony Biosciences (HRMY) - Yahoo Finance
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now? - Yahoo Finance
Does Harmony Biosciences (HRMY) Have the Potential to Rally 43.19% as Wall Street Analysts Expect? - Zacks Investment Research
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series | HRMY Stock News - GuruFocus
Harmony Biosciences CEO to Share Latest Company Updates at Exclusive H.C. Wainwright Virtual Conference - Stock Titan
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Harmony Biosciences Holdings, Inc. (HRMY) - ACCESS Newswire
Most Volatile Stocks in the US (July 2025) - Investing.com
Harmony Biosciences Reaches Settlement with Lupin Over WAKIX® Patent Litigation - MSN
Harmony Biosciences Preclinical Data for Narcolepsy Drug BP1.15205 Shows Promise - MSN
Harmony Biosciences stock resumes coverage at Goldman Sachs with Neutral rating - Investing.com Canada
Goldman Sachs Resumes Harmony Biosciences Holdings Inc. (HRMY) at Neutral - StreetInsider
6 Analysts Assess Harmony Biosciences Hldgs: What You Need To Know - Benzinga
Harmony Biosciences (HRMY) Maintains Buy Rating with Price Targe - GuruFocus
Harmony Biosciences (HRMY) Maintains Buy Rating with Price Target Increase | HRMY Stock News - GuruFocus
Harmony Biosciences stock resumes coverage at Goldman Sachs with Neutral rating By Investing.com - Investing.com South Africa
H.C. Wainwright Remains Bullish on Harmony Biosciences Holdings (HRMY) - Insider Monkey
Harmony Biosciences (HRMY) Price Target Raised by Deutsche Bank Amid Key Trial | HRMY Stock News - GuruFocus
Harmony Biosciences (HRMY) Receives Neutral Rating and Price Target from Analyst | HRMY Stock News - GuruFocus
Harmony Biosciences (HRMY) Receives Neutral Rating and Price Tar - GuruFocus
Mizuho reiterates Outperform rating on Harmony Biosciences stock By Investing.com - Investing.com Australia
SEI Select Small Cap ETF Implied Analyst Target Price: $30, Upside Potential for Underlying Holdings - AInvest
Mizuho reiterates Outperform rating on Harmony Biosciences stock - Investing.com
(HRMY) Technical Pivots with Risk Controls - news.stocktradersdaily.com
하모니 바이오 (HRMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):